13.45 USD
▼-0.30-2.18%
盘后 20.01 0.00%
2026-09-15
市值
$1.65B
市盈率
—
EPS
-2.25
股息率
—
52 周区间
13.32 – 28.23
成交量
726.41K
Beta
—
目标价
42.40
52W 低 13.3252W 高 28.23
价格走势
公司简介
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights...